Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Cuprina Holdings (Cayman)'s accounts receivables for the quarter that ended in Dec. 2025 was $0.01 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Cuprina Holdings (Cayman)'s Days Sales Outstanding for the quarter that ended in Dec. 2025 was 121.67.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Cuprina Holdings (Cayman)'s Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was $-0.09.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Cuprina Holdings (Cayman)'s Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Cuprina Holdings (Cayman)'s accounts receivable are only considered to be worth 75% of book value:
Cuprina Holdings (Cayman)'s Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Cuprina Holdings (Cayman) Accounts Receivable Related Terms
Cuprina Holdings (Cayman) Accounts Receivable Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of $0.01 Mil mean?
Cuprina Holdings (Cayman) (CUPR) has a Accounts Receivable of $0.01 Mil as of Dec. 2025. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Cuprina Holdings (Cayman) and its competitors.
Is Cuprina Holdings (Cayman)'s Accounts Receivable too high?
Cuprina Holdings (Cayman)'s current Accounts Receivable is $0.01 Mil. Overall, Cuprina Holdings (Cayman) has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Cuprina Holdings (Cayman)'s Accounts Receivable compare to BNGO and UEEC?
Cuprina Holdings (Cayman)'s Accounts Receivable of $0.01 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Medical Devices & Instruments company?
A good Accounts Receivable depends on the Medical Devices & Instruments industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Cuprina Holdings (Cayman) and its competitors. Cuprina Holdings (Cayman)'s current Accounts Receivable is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cuprina Holdings (Cayman) stock overvalued right now?
Cuprina Holdings (Cayman) (CUPR) has a current Accounts Receivable of $0.01 Mil. The current Accounts Receivable is $0.01 Mil. Cuprina Holdings (Cayman)'s overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Cuprina Holdings (Cayman) (CUPR), the current Accounts Receivable is $0.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.
10GF Score
Get the complete analysis for CUPR
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUPR has been successfully added to your 
